The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
 
Ken Masuda
No Relationships to Disclose
 
Hirokazu Shoji
No Relationships to Disclose
 
Kengo Nagashima
Consulting or Advisory Role - Fujimoto; Senju Pharmaceutical
 
Shun Yamamoto
No Relationships to Disclose
 
Masashi Ishikawa
No Relationships to Disclose
 
Hiroshi Imazeki
No Relationships to Disclose
 
Masahiko Aoki
No Relationships to Disclose
 
Takahiro Miyamoto
No Relationships to Disclose
 
Hidekazu Hirano
No Relationships to Disclose
 
Yoshitaka Honma
Speakers' Bureau - Bayer; Bristol-Myers Squibb Japan; Merck Serono; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Teijin Pharma
Research Funding - AstraZeneca; Bristol-Myers Squibb; Chugai/Roche; Daiichi Sankyo; Merck Serono; Novelpharm; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
 
Satoru Iwasa
Honoraria - Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Otsuka (Inst)
 
Natsuko Okita
No Relationships to Disclose
 
Atsuo Takashima
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - LSK BioPharma; Sumitomo Group; Takeda
 
Ken Kato
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)